

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Obinutuzumab for treating active systemic lupus erythematosus ID6670

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Roche (obinutuzumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action on Pain • AOFAC Foundation • Anthony Nolan • Arthritis Action • Arthritis & Musculoskeletal Alliance • Arthritis UK • British Sjögren’s Syndrome Association • Changing Faces • Genetic Alliance UK • Gene People • Hibbs Lupus Trust • Kidney Care UK • Kidney Research UK • Let’s Face It • Lupus Trust • Lupus UK • National Kidney Federation • National Rheumatoid Arthritis Society • Pain Concern • Pain UK • Polycystic Kidney Disease Charity • Scleroderma and Raynaud’s UK • Sjögren’s UK • South Asian Health Foundation • Specialised Healthcare Alliance • Thrombosis UK <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association of Renal Industries • Association of Renal Technologists • British Association for Surgery of the Knee 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health - Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • NHS England Specialised Rheumatology Clinical Reference Group • NHS Wales Joint Commissioning Committee • Scottish Medicines Consortium • Welsh Government <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • Baxter Healthcare (cyclophosphamide) • Blackrock Pharmaceuticals (hydroxychloroquine) • Celltrion Healthcare (rituximab) • Cipla (methotrexate) • Dr Reddy’s Laboratories (rituximab) • Esteve Pharmaceuticals (methotrexate) • GlaxoSmithKline (belimumab) • Hospira UK (methotrexate) • Ipca Laboratories (hydroxychloroquine) • Medac Pharma (methotrexate) • Morningside Healthcare (methotrexate) • Nova Laboratories (azathioprine)

Final stakeholder list for the evaluation of obinutuzumab for treating active systemic lupus erythematosus ID6670

Issue date: May 2026

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Association of Dermatologists • British Association of Urological Nurses • British Association of Urological Surgeons • British Dermatological Nursing Group • British Geriatrics Society • British Isles Lupus Assessment Group • British Myology Society • British Orthopaedic Association • British Orthopaedic Foot and Ankle Society • British Society for Allergy and Clinical Immunology • British Society for Children’s Orthopaedic Surgery • British Society for Haematology • BSI Clinical Immunology Professional Network (BSI-CIPN) • British Society for Haemostasis and Thrombosis • British Society for Rheumatology • British Society of Physical and Rehabilitation Medicine • British Thoracic Society • Clinical Leaders of Thrombosis • Physiotherapy Pain Association • Primary Care Dermatology Society • Primary Care Rheumatology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for DGH Nephrologists • Society for Endocrinology • Society for Vascular Technology • Society for Vascular Ultrasound • Society of Vascular Nurses • UK Clinical Pharmacy Association • UK Kidney Association • UK Renal Pharmacy Group • Urology Foundation 	<ul style="list-style-type: none"> • Organon Pharma (methotrexate) • Pfizer (rituximab) • Rosemont Pharmaceuticals (methotrexate, mycophenolate mofetil) • Sandoz (rituximab, cyclophosphamide, methotrexate) • Seacross Pharmaceuticals (cyclophosphamide) • Strides Pharma UK (azathioprine) • Teva Pharma (mycophenolate mofetil) • Tillomed Laboratories (azathioprine, mycophenolate mofetil) • Zentiva (hydroxychloroquine) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bone Research Society • British Skin Foundation • Centre of Evidence-Based Dermatology, University of Nottingham • Chronic Pain Policy Coalition • Cochrane Heart, Stroke and Circulation • Cochrane Kidney and Transplant Group • Cochrane Musculoskeletal Group • Cochrane Skin Group • Dermatrust • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • Orthopaedic Research UK • Pain Relief Foundation • Thrombosis Research Institute <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Vascular Society of Great Britain and Ireland <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

